SI2987796T1 - Halogen-substituirani boronoftalidi za zdravljenje okužb - Google Patents

Halogen-substituirani boronoftalidi za zdravljenje okužb

Info

Publication number
SI2987796T1
SI2987796T1 SI200632291T SI200632291T SI2987796T1 SI 2987796 T1 SI2987796 T1 SI 2987796T1 SI 200632291 T SI200632291 T SI 200632291T SI 200632291 T SI200632291 T SI 200632291T SI 2987796 T1 SI2987796 T1 SI 2987796T1
Authority
SI
Slovenia
Prior art keywords
boronophthalides
infections
halogen
substituted
treatment
Prior art date
Application number
SI200632291T
Other languages
English (en)
Slovenian (sl)
Inventor
Stephen Baker
Tsutomu Akama
Carolyn Bellinger-Kawahara
Vincent Hernandez
Karin Hold
James Leyden
Kirk Maples
Jacob J Plattner
Virginia Sanders
Yong-Kang Zhang
Original Assignee
Anacor Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36917059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2987796(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anacor Pharmaceuticals, Inc. filed Critical Anacor Pharmaceuticals, Inc.
Publication of SI2987796T1 publication Critical patent/SI2987796T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200632291T 2005-02-16 2006-02-16 Halogen-substituirani boronoftalidi za zdravljenje okužb SI2987796T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65406005P 2005-02-16 2005-02-16
EP15171026.6A EP2987796B1 (en) 2005-02-16 2006-02-16 Halogen-substituted boronophthalides for the treatment of infections

Publications (1)

Publication Number Publication Date
SI2987796T1 true SI2987796T1 (sl) 2018-11-30

Family

ID=36917059

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200632291T SI2987796T1 (sl) 2005-02-16 2006-02-16 Halogen-substituirani boronoftalidi za zdravljenje okužb
SI200632404T SI3424932T1 (sl) 2005-02-16 2006-02-16 Boronoftalidi za terapevtsko uporabo
SI200631937T SI2343304T1 (sl) 2005-02-16 2006-02-16 Biocidne boroftalidne spojine

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200632404T SI3424932T1 (sl) 2005-02-16 2006-02-16 Boronoftalidi za terapevtsko uporabo
SI200631937T SI2343304T1 (sl) 2005-02-16 2006-02-16 Biocidne boroftalidne spojine

Country Status (26)

Country Link
US (11) US7582621B2 (enExample)
EP (4) EP2987796B1 (enExample)
JP (6) JP5038912B2 (enExample)
KR (4) KR101337068B1 (enExample)
CN (2) CN101914109B (enExample)
AU (3) AU2006214247C1 (enExample)
BE (1) BE2020C531I2 (enExample)
BR (1) BRPI0608431B8 (enExample)
CA (1) CA2597982C (enExample)
CY (3) CY1120695T1 (enExample)
DK (3) DK3424932T3 (enExample)
ES (4) ES2872962T3 (enExample)
FR (1) FR20C1024I2 (enExample)
HU (4) HUE026021T2 (enExample)
IL (2) IL207156A (enExample)
LT (1) LTC2343304I2 (enExample)
LU (1) LUC00157I2 (enExample)
MX (1) MX369262B (enExample)
NL (1) NL301049I2 (enExample)
NZ (3) NZ578297A (enExample)
PL (4) PL2343304T3 (enExample)
PT (4) PT3424932T (enExample)
RU (3) RU2414906C2 (enExample)
SI (3) SI2987796T1 (enExample)
WO (1) WO2006089067A2 (enExample)
ZA (4) ZA200707408B (enExample)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820186B2 (en) * 2001-12-21 2010-10-26 Galderma Research & Development Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
ES2872962T3 (es) 2005-02-16 2021-11-03 Anacor Pharmaceuticals Inc Boronoftalidas para uso terapéutico
US7793666B2 (en) * 2005-07-28 2010-09-14 Innovation Biomedical Devices, Inc. Apparatus and method for treatment of infected nail
CA2635680A1 (en) 2005-12-30 2007-07-12 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
KR20080110751A (ko) * 2006-02-16 2008-12-19 아나코르 파마슈티칼스 인코포레이티드 항염증제로서 보론함유 소분자
JP2009536660A (ja) * 2006-05-02 2009-10-15 アナコール ファーマシューティカルズ，インコーポレイテッド 加水分解耐性ホウ素含有治療剤及びその使用方法
EP1900378A1 (en) * 2006-08-31 2008-03-19 Novartis AG Pharmaceutical compositions for the treatment of fungal infections
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
FR2910321B1 (fr) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc Gel creme comprenant au moins un retinoide et du peroxyde de benzole
FR2910320B1 (fr) * 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprenant au moins un retinoide et du peroxyde de benzole
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
JP2015178508A (ja) * 2008-01-09 2015-10-08 アナコール ファーマシューティカルズ，インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
WO2009111676A2 (en) * 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
EP3246034A1 (en) 2008-03-06 2017-11-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
CA2721060A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US20100256092A1 (en) * 2008-05-12 2010-10-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010011354A2 (en) * 2008-07-25 2010-01-28 Innovation Biomedical Devices, Inc. Enchanced trans-keratin drug delivery
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2348863A4 (en) * 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
CN102256494A (zh) 2008-12-17 2011-11-23 阿纳科制药公司 (s)-3-氨甲基-7-(3-羟基-丙氧基)-3h-苯并[c][1,2]氧杂硼杂环戊-1-醇的多晶型物
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2417115A4 (en) 2009-04-07 2012-10-31 Infinity Pharmaceuticals Inc FATTY ACID AMIDE HYDROLASE INHIBITORS
RU2012107163A (ru) 2009-07-28 2013-09-10 Анакор Фармасьютикалз, Инк. Тризамещенные борсодержащие молекулы
WO2011019612A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US9440994B2 (en) 2009-08-14 2016-09-13 Anacor Pharmaceuticals, Inc. Boron containing small molecules as antiprotozoal agents
WO2011019616A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US20110207701A1 (en) * 2009-08-19 2011-08-25 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
US8979820B2 (en) 2009-10-09 2015-03-17 Cynthia S. Bailey Method and apparatus for improving the appearance of nails affected by onychomycosis through the topical application of an aqueous solution containing boric acid and camphor or other terpenes
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011060199A1 (en) 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011063293A1 (en) 2009-11-20 2011-05-26 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antihelminth agents
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
RU2569061C2 (ru) 2010-02-03 2015-11-20 Инфинити Фармасьютикалз, Инк. Ингибиторы амид-гидролазы жирных кислот
WO2011116348A1 (en) 2010-03-19 2011-09-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
RU2432158C1 (ru) * 2010-07-28 2011-10-27 Закрытое акционерное общество "Институт прикладной нанотехнологии" Профилактический бактерицидный лак для обработки ногтей
BR112013003045B1 (pt) 2010-08-10 2021-08-31 Rempex Pharmaceuticals, Inc. Composto e respectivo uso, composição farmacêutica, recipiente estéril e método para preparar composição farmacêutica para administração
WO2012033858A2 (en) 2010-09-07 2012-03-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013049424A1 (en) 2011-09-28 2013-04-04 Wisconsin Alumni Research Foundation Catalytic conversion of cellulose to fuels and chemicals using boronic acids
US10130096B2 (en) 2011-10-07 2018-11-20 Syngenta Participations Ag Method for protecting useful plants or plant propagation material
AR088668A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014007831A1 (en) 2012-07-06 2014-01-09 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014107535A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EA201591004A1 (ru) 2013-01-04 2016-02-29 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US8669207B1 (en) 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
US9585396B2 (en) 2013-01-30 2017-03-07 Agrofresh Inc. Volatile applications against pathogens
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
CN107646865B (zh) 2013-01-30 2020-07-03 美国陶氏益农公司 苯硼酸半酯作为挥发性抗微生物剂在肉类、植物或植物部分上的用途
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9598443B2 (en) 2013-02-01 2017-03-21 Anacor Pharmaceuticals, Inc. Boron containing small molecules as antiprotozoal agents
AR094961A1 (es) 2013-03-15 2015-09-09 Lilly Co Eli 1-hidroxi-benzooxaboroles como agentes antiparasitarios
AU2014202928B1 (en) * 2013-06-05 2014-09-11 Agrofresh Inc. Compounds and compositions
CN104224810B (zh) * 2013-06-20 2017-04-19 中国科学院上海生命科学研究院 一种化合物及其衍生物治疗肺炎球菌感染性疾病的用途
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
NZ716350A (en) * 2013-08-09 2022-12-23 Glaxosmithkline Ip No 2 Ltd Tricyclic benzoxaborole compounds and uses thereof
AU2014329421B2 (en) 2013-10-03 2018-08-02 Dow Pharmaceutical Sciences, Inc. Stabilized efinaconazole compositions
JP6611014B2 (ja) 2013-11-22 2019-11-27 ボシュ ヘルス アイルランド リミテッド 抗感染方法、抗感染組成物、および抗感染装置
CA2938799A1 (en) 2014-02-17 2015-08-20 Syngenta Paticipations Ag Microbiocidally active benzoxaboroles
WO2015134500A1 (en) 2014-03-03 2015-09-11 Cook Medical Technologies Llc Mechanical dilator
ES2985626T3 (es) 2014-05-05 2024-11-06 Melinta Therapeutics Inc Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos
EP3604316B1 (en) 2014-05-05 2023-12-06 Melinta Therapeutics, Inc. Synthesis of boronate salts
JP2015212249A (ja) * 2014-05-05 2015-11-26 アナコール ファーマシューティカルズ，インコーポレイテッド 化合物および爪光沢剤
SG11201609020VA (en) * 2014-05-12 2016-11-29 Agrofresh Inc Volatile applications against pathogens
EA201691988A1 (ru) 2014-05-19 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
EP3164404B1 (en) * 2014-07-01 2019-04-03 Daiichi Sankyo Company, Limited Tricyclic benzoxaboroles as antibacterial agents
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6646662B2 (ja) 2014-10-21 2020-02-14 ヘキシマ リミテッド 治療方法
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
MA41495A (fr) 2015-02-12 2017-12-19 Anacor Pharmaceuticals Inc Composés benzoxaborole et leurs utilisations
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR101580077B1 (ko) * 2015-03-28 2015-12-24 한국콜마주식회사 시크로피록스 함유 네일락카 조성물
CN107872956B (zh) 2015-04-09 2020-07-10 宾夕法尼亚州研究基金会 含有苯并氧杂硼戊环的协同性抗真菌组合物
CA2979891A1 (en) 2015-04-09 2016-10-13 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2016201440A1 (en) * 2015-06-12 2016-12-15 The Regents Of The University Of California Spiroindolinones and therapeutic uses thereof
US10160867B2 (en) * 2015-08-06 2018-12-25 The Penn State Research Foundation Benzoxaborole-containing coating resistant to cellulose-supportable fungus
CN106467557B (zh) * 2015-08-18 2019-05-03 北京海美桐医药科技有限公司 他瓦硼罗的一种制备方法
IL259693B2 (en) 2015-11-30 2025-01-01 Anacor Pharmaceuticals Llc Topical preparations and their use in the treatment of inflammation
CN113563368A (zh) 2016-03-02 2021-10-29 比尔及梅琳达盖茨基金会 含硼小分子
US10874679B2 (en) 2016-03-02 2020-12-29 Bill & Melinda Gates Foundation Boron-containing small molecules
WO2017151492A1 (en) * 2016-03-02 2017-09-08 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2017155879A1 (en) 2016-03-07 2017-09-14 Agrofresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
WO2017155877A1 (en) 2016-03-07 2017-09-14 Agrofresh Inc. Vaporized administration of pesticides
EP3456722B1 (en) * 2016-05-09 2025-12-10 Anacor Pharmaceuticals, LLC Crystal forms of crisaborole in free form and preparation method and use thereof
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
ES2894251T3 (es) 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
WO2018013655A1 (en) 2016-07-12 2018-01-18 Pliva Hrvatska D.O.O. Solid state forms of crisaborole
US10743232B1 (en) 2016-11-15 2020-08-11 Sprint Spectrum L.P. Controlling handover based on carrier-aggregation policies and UE capabilities
WO2018115362A1 (en) 2016-12-22 2018-06-28 Laboratorios Lesvi, Sl Process for preparing 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile (crisaborole)
GB201701583D0 (en) * 2017-01-31 2017-03-15 Drug Delivery Solutions Ltd Topical composition
WO2018150327A1 (en) * 2017-02-14 2018-08-23 Wavelength Enterprises Ltd Crisaborole production process
CA3054138A1 (en) 2017-03-09 2018-09-13 The Penn State Research Foundation Boron-containing small molecules for inhibiting activity of a receptor-like protein tyrosine phosphatase
WO2018207216A1 (en) 2017-05-12 2018-11-15 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl) oxy] benzonitrile (crisaborole)
US10865217B2 (en) 2017-05-23 2020-12-15 Msn Laboratories Private Limited, R & D Center Process for the preparation of 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole and polymorphs thereof
CA3078627A1 (en) 2017-10-11 2019-04-18 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
EP4119566A1 (en) 2017-11-02 2023-01-18 Halcyon Labs Private Limited Novel process for the preparation tavaborole and its intermediates
US11834466B2 (en) * 2017-11-30 2023-12-05 5Metis, Inc. Benzoxaborole compounds and formulations thereof
US10329311B1 (en) 2017-12-21 2019-06-25 Olon S.P.A. Process for the preparation of crisaborole
CN108148085B (zh) 2018-01-04 2019-11-01 合肥医工医药股份有限公司 具有抑制磷酸二酯酶4的化合物、制法及其药物用途
BR112020013794B1 (pt) 2018-01-09 2023-05-02 Halcyon Labs Private Limited Processo para a preparação de crisaborola de fórmula (i), compostos, uso de um composto de fórmula (iv), (iii) ou (ii), processo para a preparação de crisaborola altamente pura e sal
US10597410B2 (en) 2018-02-02 2020-03-24 Dipharma Francis S.R.L. Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent
CN108451898A (zh) * 2018-04-03 2018-08-28 苏州尚宜佳生物科技有限公司 一种克立硼罗温敏凝胶剂及其制备方法和应用
US12016868B2 (en) 2018-04-20 2024-06-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
GB201809378D0 (en) * 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
CN108659024A (zh) * 2018-07-24 2018-10-16 武汉轻工大学 克立硼罗的制备方法
JP7268132B2 (ja) * 2018-07-31 2023-05-02 エムシー２・セラピューティクス・リミテッド 局所用組成物
MX2021001904A (es) 2018-08-18 2021-05-27 Boragen Inc Formas solidas de benzoxaborol sustituido y composiciones de las mismas.
CA3114702C (en) * 2018-10-05 2023-08-08 Pfizer Inc. Boron containing pde4 inhibitors
US20220160649A1 (en) 2019-03-20 2022-05-26 Rita DOBMEYER Pharmaceutical composition
US12065456B2 (en) * 2019-07-25 2024-08-20 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Boron-containing pharmacophore
CN110664756B (zh) * 2019-10-09 2020-11-17 吉林大学 一种小儿外伤喷雾剂及其制备方法
EP4204012A1 (en) 2020-08-31 2023-07-05 Pfizer Inc. Methods of protecting rna
CN114644645B (zh) * 2022-03-08 2023-05-26 南京农业大学 3-吲哚取代苯硼唑类化合物及其制备方法和应用
JP2025520237A (ja) 2022-06-23 2025-07-03 ミクウルク ファーマシューティカルズ， インコーポレイテッド ホウ素化合物を用いて非結核性マイコバクテリア感染症を治療する方法及びその用途、並びに同じ疾患を治療するための医薬組成物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2260336A (en) 1939-10-16 1941-10-28 Dow Chemical Co Method of preparation of organic borates
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
GB1396904A (en) * 1972-08-11 1975-06-11 Ici Ltd Method for the control of micro-organisms
US4766113A (en) 1975-10-24 1988-08-23 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4602011A (en) 1975-10-24 1986-07-22 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4716035A (en) 1985-05-24 1987-12-29 The Procter & Gamble Company Oral compositions and methods for treating gingivitis
US5962498A (en) 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US4894220A (en) 1987-01-30 1990-01-16 Colgate-Palmolive Company Antibacterial antiplaque oral composition
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5348948A (en) 1993-05-07 1994-09-20 American Cyanamid Company 2,2-diaryl-1-(oxa and thia)-2a-azonia-2-borataacenaphthene fungicidal
US5348947A (en) 1993-05-07 1994-09-20 American Cyanamid Company Diarylboron ester and thioester fungicidal agents
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
GB9411587D0 (en) * 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US5688258A (en) 1995-05-02 1997-11-18 The Procter & Gamble Company Disposable cover for an absorbent materials
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
GB9500856D0 (en) * 1995-01-17 1995-03-08 Zeneca Ltd Composition and use
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US6766183B2 (en) 1995-11-22 2004-07-20 Medtronic Minimed, Inc. Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymers
US6632955B1 (en) 1996-12-02 2003-10-14 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
US5831046A (en) 1996-08-05 1998-11-03 Prolinx, Incorporated Boronic acid-contaning nucleic acid monomers
US6413751B1 (en) 1996-09-19 2002-07-02 The Board Of Trustees Of The Leland Stanford Jr. University DNA adenine methyltransferases and uses thereof
US6221640B1 (en) 1997-05-14 2001-04-24 Cubist Pharmaceuticals, Inc. Enterococcal aminoacyl-trna synthetase proteins, nucleic acids and strains comprising same
US6140328A (en) 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
DE19829947A1 (de) 1998-07-04 2000-01-05 Bayer Ag Elektrolumineszierende Anordnungen mit Bor-Chelaten
IL142584A0 (en) 1998-11-06 2002-03-10 Basf Ag Tricyclic pyrazole derivatives
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
EP1155698A4 (en) 1999-01-29 2003-01-15 Nitto Kasei Co Ltd ORGANOBORAL COMPOUNDS HAVING COCCIDIOSTAT ACTIVITY
EP1181291A2 (en) 1999-05-25 2002-02-27 The Penn State Research Foundation Dna methyltransferase inhibitors
US6306628B1 (en) 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
EP1210449B1 (en) 1999-08-25 2006-12-27 Ambergen, Inc. Methods for the detection, analysis and isolation of nascent proteins
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
WO2001025226A1 (en) 1999-10-05 2001-04-12 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
WO2001049301A1 (en) 2000-01-06 2001-07-12 Marantech Holding, Llc Methods of using electron active compounds for managing cancer
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
JP2004506417A (ja) 2000-07-14 2004-03-04 ザイコス　インク． α−ＭＳＨ関連化合物および使用方法
US6642252B2 (en) 2000-11-07 2003-11-04 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
JP2004524281A (ja) 2000-11-30 2004-08-12 ザ ペン ステート リサーチ ファウンデイション Ｄｎａメチルトランスフェラーゼ阻害剤
DE10110051C2 (de) 2001-03-02 2003-07-03 Clariant Gmbh Verfahren zur Herstellung von Boron- und Borinsäuren
ATE438615T1 (de) 2001-04-06 2009-08-15 Biocryst Pharm Inc Biarylverbindungen als serinproteaseinhibitoren
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
DE10143979A1 (de) 2001-09-07 2003-03-27 Clariant Gmbh Verfahren zur Herstellung von Bisallylboranen und nicht-aromatischen Boronsäuren
EP1444981A1 (en) 2001-10-11 2004-08-11 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
AU2003205089B2 (en) 2002-01-10 2007-01-25 The Pennsylvania State Research Foundation Methods for the preparation of alkyl diaryl borinates and complexed diarylborinic acids
IL166157A0 (en) 2002-07-09 2006-01-15 Point Therapeutics Inc Methods and compositions relating to isoleucine boroproline compounds
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
ATE359986T1 (de) 2002-12-02 2007-05-15 Solvias Ag Verfahren zur katalytischen hydrierung von kohlenstoff-heteroatom-doppelbindungen
NZ540870A (en) 2002-12-18 2008-09-26 Anacor Pharmaceuticals Inc Antibiotics containing borinic acid complexes and methods of use
US7390806B2 (en) 2002-12-18 2008-06-24 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
EP1613625A1 (en) 2003-03-14 2006-01-11 AstraZeneca AB Novel fused triazolones and the uses thereof
WO2005000200A2 (en) 2003-05-09 2005-01-06 Sugen, Inc. Novel kinases
MXPA05013848A (es) 2003-06-16 2006-09-04 Anacor Pharmaceuticals Inc Agentes terapeuticos que contienen boro hidroliticamente resistentes y metodos de uso.
JP2005022986A (ja) * 2003-06-30 2005-01-27 Sankyo Co Ltd Ｅｄｇ受容体拮抗作用を有するアルキン誘導体
DK1643998T3 (da) 2003-07-03 2007-12-27 Hoffmann La Roche NK1/NK3-antagonister til behandling af skizofreni
EP1699792A1 (en) 2003-12-29 2006-09-13 3M Innovative Properties Company Piperazine, 1,4¨diazepane, 1,4¨diazocane, and 1,5¨diazocane fused imidazo ring compounds
ES2464444T3 (es) 2004-05-12 2014-06-02 The Brigham And Women's Hospital, Inc. Gelsolina para uso en el tratamiento de infecciones
AR049915A1 (es) 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
KR100624238B1 (ko) 2004-06-22 2006-09-19 한국화학연구원 알파-아릴메톡시아크릴레이트 유도체를 함유하는 대사성골 질환의 예방 및 치료용 약학 조성물
US20060111388A1 (en) 2004-11-19 2006-05-25 University Of North Texas Health Science Center At Fort Worth Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
GB0501944D0 (en) 2005-01-31 2005-03-09 Univ Cambridge Tech Compounds for use in chemical detection and/or quantitation
ES2872962T3 (es) * 2005-02-16 2021-11-03 Anacor Pharmaceuticals Inc Boronoftalidas para uso terapéutico
US7919422B2 (en) 2005-03-08 2011-04-05 Agency For Science, Technology And Research Chiral bisoxazoline catalysts
UY29449A1 (es) 2005-03-30 2006-10-02 Astion Dev As Tratamiento de enfermedades dermatólogicas y del prurito.
WO2007022437A2 (en) 2005-08-18 2007-02-22 Auspex Pharmaceuticals, Inc. Therapeutic agents for the treatment of cancer and metabolic disorders
CA2635680A1 (en) 2005-12-30 2007-07-12 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
KR20080110751A (ko) 2006-02-16 2008-12-19 아나코르 파마슈티칼스 인코포레이티드 항염증제로서 보론함유 소분자
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
BRPI0713010A2 (pt) 2006-06-12 2012-10-09 Anacor Pharmaceuticals Inc compostos para o tratamento de doença periodontal
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
KR100895300B1 (ko) 2007-07-20 2009-05-07 한국전자통신연구원 생체신호 측정의복과 생체신호 처리시스템
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
EP3246034A1 (en) 2008-03-06 2017-11-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
US20100256092A1 (en) 2008-05-12 2010-10-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010045505A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-protozoal agents
US9493489B2 (en) 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
AR088668A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
AR088669A1 (es) * 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos

Also Published As

Publication number Publication date
ZA200905950B (en) 2010-11-24
IL185080A0 (en) 2008-08-07
HK1160139A1 (en) 2012-08-10
KR20070112390A (ko) 2007-11-23
CN101160124A (zh) 2008-04-09
NZ598441A (en) 2013-07-26
HUS2000019I1 (hu) 2020-07-28
EP1853251A2 (en) 2007-11-14
KR101426220B1 (ko) 2014-08-05
ES2414095T3 (es) 2013-07-18
RU2606947C2 (ru) 2017-01-10
US8440642B2 (en) 2013-05-14
AU2010203096A1 (en) 2010-08-12
PT2343304E (pt) 2015-08-26
US20170066788A1 (en) 2017-03-09
LUC00157I2 (enExample) 2021-07-06
PT1853251E (pt) 2013-07-19
PL3424932T3 (pl) 2021-09-20
DK2987796T3 (en) 2018-09-17
JP6046876B2 (ja) 2016-12-21
KR20100105869A (ko) 2010-09-30
HUE040060T2 (hu) 2019-02-28
EP3424932B1 (en) 2021-04-07
US8039451B2 (en) 2011-10-18
NZ560448A (en) 2009-08-28
LTPA2020524I1 (lt) 2020-09-10
EP3424932A1 (en) 2019-01-09
JP5038912B2 (ja) 2012-10-03
JP2016020374A (ja) 2016-02-04
EP1853251A4 (en) 2010-01-13
US7582621B2 (en) 2009-09-01
BRPI0608431A2 (pt) 2009-12-29
US20060234981A1 (en) 2006-10-19
PT3424932T (pt) 2021-05-19
AU2010203096C1 (en) 2012-09-20
EP2343304B1 (en) 2015-06-10
US20150065459A1 (en) 2015-03-05
KR101337045B1 (ko) 2013-12-05
ES2540966T3 (es) 2015-07-15
KR20130095330A (ko) 2013-08-27
PL2987796T3 (pl) 2018-12-31
US20190330245A1 (en) 2019-10-31
US20190048026A1 (en) 2019-02-14
IL185080A (en) 2012-07-31
KR101337068B1 (ko) 2013-12-06
EP2987796A1 (en) 2016-02-24
CY1124503T1 (el) 2022-07-22
AU2011200994A1 (en) 2011-03-31
RU2414906C2 (ru) 2011-03-27
AU2010203096B2 (en) 2010-12-02
AU2006214247B2 (en) 2010-08-05
PL1853251T3 (pl) 2013-09-30
RU2010133524A (ru) 2012-02-20
BRPI0608431B1 (pt) 2020-09-15
JP2017105826A (ja) 2017-06-15
SI2343304T1 (sl) 2015-08-31
HK1221956A1 (en) 2017-06-16
EP2987796B1 (en) 2018-08-08
ZA201506944B (en) 2018-08-29
ZA201005380B (en) 2016-08-31
ES2872962T3 (es) 2021-11-03
SI3424932T1 (sl) 2021-08-31
ZA200707408B (en) 2009-11-25
AU2006214247C1 (en) 2012-11-08
FR20C1024I2 (fr) 2021-07-09
AU2006214247A1 (en) 2006-08-24
CY2020027I1 (el) 2021-01-27
NL301049I2 (nl) 2020-09-10
WO2006089067A3 (en) 2007-07-19
HUE026021T2 (en) 2016-05-30
JP2014132031A (ja) 2014-07-17
BE2020C531I2 (enExample) 2025-09-05
JP2013018778A (ja) 2013-01-31
IL207156A (en) 2014-04-30
EP2343304A1 (en) 2011-07-13
LUC00157I1 (enExample) 2020-06-08
EP1853251B1 (en) 2013-04-24
MX369262B (es) 2019-11-04
US20110319361A1 (en) 2011-12-29
CA2597982A1 (en) 2006-08-24
KR101456815B1 (ko) 2014-10-31
US20130244980A1 (en) 2013-09-19
JP2008535781A (ja) 2008-09-04
KR20130100019A (ko) 2013-09-06
JP2010248265A (ja) 2010-11-04
FR20C1024I1 (enExample) 2020-07-31
RU2016145916A3 (enExample) 2020-07-21
US20140142064A1 (en) 2014-05-22
CY1120695T1 (el) 2019-12-11
DK3424932T3 (da) 2021-05-25
ES2686981T3 (es) 2018-10-23
NL301049I1 (nl) 2020-07-01
RU2007134429A (ru) 2009-03-27
RU2016145916A (ru) 2018-05-23
CY2020027I2 (el) 2021-01-27
HK1109735A1 (en) 2008-06-20
PT2987796T (pt) 2018-10-18
CA2597982C (en) 2014-07-08
US8889656B2 (en) 2014-11-18
PL2343304T3 (pl) 2015-09-30
LTC2343304I2 (lt) 2022-11-10
BRPI0608431B8 (pt) 2021-05-25
DK2343304T3 (en) 2015-06-29
HUE054365T2 (hu) 2021-09-28
CN101914109A (zh) 2010-12-15
US20100190748A1 (en) 2010-07-29
WO2006089067A2 (en) 2006-08-24
US20210070780A1 (en) 2021-03-11
US20160108063A1 (en) 2016-04-21
NZ578297A (en) 2010-11-26
CN101914109B (zh) 2014-07-23

Similar Documents

Publication Publication Date Title
PL2987796T3 (pl) Fluorowco-podstawione boronoftalidy do leczenia zakażeń
IL187999A0 (en) Compositions for the treatment of persistent infections
IL184955A0 (en) Tricyclic-nucleoside compounds for treating viral infections
GB0513552D0 (en) Bandage
IL191379A (en) sewage care
IL187581A0 (en) Compounds for the treatment of multi-drug resistant bacterial infections
ZA200709875B (en) Loincloth diaper
ZA200705783B (en) Amino-imidazolones for the inhibition of ß-secretase
IL190913A0 (en) Methods for the treatment of hyperhidrosis
IL186408A0 (en) Combination treatment methods
PL1951334T3 (pl) Laktator
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
GB0524103D0 (en) Healing
GB0513096D0 (en) Treatment of microbial infections
GB0518508D0 (en) Treatment of waste
GB0516068D0 (en) Well treatment
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
PL1959957T3 (pl) Pochodne pirymidyloaminobenzamidu do leczenia neurowłókniakowatości
GB0511769D0 (en) Treatment
GB0525540D0 (en) New treatment
GB0517387D0 (en) Combinations for the treatment of cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
GB0621587D0 (en) Sludge treatment
GB0502171D0 (en) Well treatment
EP1841457A4 (en) TARGET APHERESIS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS